Literature DB >> 18193432

Serum sulfatase activity is more elevated in colonic adenomas than cancers.

Malgorzata Matusiewicz1, Malgorzata Krzystek-Korpacka, Dorota Diakowska, Krzysztof Grabowski, Katarzyna Augoff, Katarzyna Blachut, Leszek Paradowski, Irena Kustrzeba-Wojcicka, Michal Piast, Teresa Banas.   

Abstract

BACKGROUND AND AIMS: Elucidation of molecular basis of the adenomatous polyps (AP) and colorectal cancer (CRC) development is crucial for their prevention, early detection, and treatment. According to the recent discoveries, sulfatases are implied in extracellular matrix remodeling and degradation and also in the regulation of certain signaling pathways. However, their exact role in carcinogenesis remains unclear. Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas. PATIENT-
METHODS: One hundred twenty individuals were enrolled in the study. We assayed serum sulfatase activity in 79 patients with colorectal neoplasms (38 CRC and 41 AP) and 41 controls. Enzyme activity was determined colorimetrically.
RESULTS: We found statistically higher serum sulfatase activity in patients with colonic neoplasms than in controls (124; 112-139 vs. 79.5; 73-87 U). The activity was more elevated in adenomas (149; 128-173 U) than in cancers (103; 90-112 U). Sulfatase activity exceeded the cutoff value in 71% of AP and 47% of CRC patients. It increased with number of adenomas and tended to decrease with tumor progression.
CONCLUSIONS: Sulfatases seem to be involved in the early stages of colonic neoplastic transformation which is reflected in their serum activity. The likelihood of elevated sulfatase activity is almost ten times higher in subjects with than without polyps. Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193432     DOI: 10.1007/s00384-007-0434-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  19 in total

1.  Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis.

Authors:  Dongfang Liu; Zachary Shriver; Ganesh Venkataraman; Yosuf El Shabrawi; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  WNT/PCP signaling pathway and human cancer (review).

Authors:  Masaru Katoh
Journal:  Oncol Rep       Date:  2005-12       Impact factor: 3.906

3.  Arylsulfatase A in serum from patients with cancer of various organs.

Authors:  P Laidler; D Kowalski; J Silberring
Journal:  Clin Chim Acta       Date:  1991-12-31       Impact factor: 3.786

4.  Measurements of arylsulfatases A and B in human serum.

Authors:  J Singh; D Tavella; N D Ferrante
Journal:  J Pediatr       Date:  1975-04       Impact factor: 4.406

5.  Arylsulfatse B in colorectal cancer.

Authors:  L R Morgan; M S Samuels; W Thomas; E T Krementz; W Meeker
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

6.  Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma.

Authors:  A Woźniak; T Drewa; M Rozwodowska; G Drewa; W Lambrecht; I Wiśniewska
Journal:  Neoplasma       Date:  2002       Impact factor: 2.575

7.  Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.

Authors:  Hikmet Koçak; Yildiz Oner-Iyidoğan; Taner Koçak; Pernur Oner
Journal:  Clin Biochem       Date:  2004-08       Impact factor: 3.281

Review 8.  Sulfatases and human disease.

Authors:  Graciana Diez-Roux; Andrea Ballabio
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

9.  Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer.

Authors:  Junsheng Li; Jörg Kleeff; Ivane Abiatari; Hany Kayed; Nathalia A Giese; Klaus Felix; Thomas Giese; Markus W Büchler; Helmut Friess
Journal:  Mol Cancer       Date:  2005-04-07       Impact factor: 27.401

10.  Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.

Authors:  R A Wagenaar-Miller; G Hanley; R Shattuck-Brandt; R N DuBois; R L Bell; L M Matrisian; D W Morgan
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more
  3 in total

1.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

2.  Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.

Authors:  Loretta De Chiara; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; Oscar J Cordero; David Martínez-Ares; María Páez de la Cadena
Journal:  BMC Cancer       Date:  2010-06-28       Impact factor: 4.430

3.  TAZ expression as a prognostic indicator in colorectal cancer.

Authors:  Hiu-Fung Yuen; Cian M McCrudden; Yu-Han Huang; Jill M Tham; Xiaoqian Zhang; Qi Zeng; Shu-Dong Zhang; WanJin Hong
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.